Key statistics
On Friday, Exelixis Inc (EX9:MUN) closed at 37.69, -14.02% below its 52-week high of 43.83, set on Jun 23, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 37.69 |
|---|---|
| High | 37.69 |
| Low | 37.23 |
| Bid | 36.38 |
| Offer | 37.68 |
| Previous close | 37.82 |
| Average volume | 274.20 |
|---|---|
| Shares outstanding | 259.71m |
| Free float | 253.47m |
| P/E (TTM) | 15.67 |
| Market cap | 11.33bn USD |
| EPS (TTM) | 2.78 USD |
Data delayed at least 15 minutes, as of Feb 20 2026 08:05 GMT.
More ▼
- Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
- Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
- Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026
- Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer
- Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026
- Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025
More ▼
